Imunon Inc
IMNN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.5M
Close$
$3.66
74.3% upside
Current Fair Value
74.3% upsideUndervalued by 74.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.50 Million |
|---|---|
| Enterprise Value | $1.61 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.83 |
| Beta | 2.03 |
| Outstanding Shares | 5,029,000 |
Return
| Return on Equity | -102402.21% |
|---|---|
| Return on Assets | -42903.85% |
| Return on Invested Capital | -89304.37% |
Valuation & Multiples
| P/E Ratio | -0.75 |
|---|---|
| PEG | -20.96 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.56 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.81
Average shareholder expectationRevenue Estimate
$-674,876
Average shareholder expectationNext Earnings Call
Expected Date
August 4, 2026
EPS Estimate
$-0.95
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 10.01%▼ 10.33% |
|---|---|
| Total Invested | $1.63M▼ 7.69% |
| Investors Holding | 18▼ 1.00% |
ESG Score
No data
About Imunon Inc
27 employees
CEO: Michael Tardugno Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid v...